Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
      Description

      The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.

      Conditions
      BRAF or NRAS Mutant Metastatic Melanoma
      Talk to us
      COMPLETED
      A Study of ASN007 in Patients With Advanced Solid Tumors
      Description

      The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

      Conditions
      CancerMalignancyNeoplasiaNeoplasmNeoplasm MetastasisColon CancerColonic NeoplasmsColon Cancer Liver MetastasisMetastatic CancerMetastatic MelanomaMetastatic Colon CancerMetastatic Lung CancerNon Small Cell Lung Cancer MetastaticPancreatic CancerPancreas CancerPancreas AdenocarcinomaPancreas NeoplasmMetastatic Nonsmall Cell Lung CancerMetastatic Pancreatic Cancer
      Talk to us
      COMPLETED
      A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
      Description

      This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.

      Conditions
      Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung CancerMalignant Melanoma (Cutaneous)
      Talk to us